ARA-290

What is ARA-290?

ARA-290 (cibinetide) is an 11-amino-acid synthetic peptide modeled on helix B of the erythropoietin (EPO) molecule. It was designed to retain EPO's tissue-protective and anti-inflammatory effects while eliminating the erythropoietic activity (red blood cell stimulation) that causes EPO's cardiovascular side effects. ARA-290 activates the innate repair receptor (IRR) — a heteromer of the EPO receptor and the β-common receptor — which is transiently expressed on injured tissues to initiate repair, reduce inflammation, and protect cells from further damage. The peptide has advanced through multiple Phase 2 trials, most notably in sarcoidosis-associated small fiber neuropathy and type 2 diabetes neuropathy.

What ARA-290 Is Investigated For

ARA-290 (cibinetide) is investigated for small fiber neuropathy, diabetic peripheral neuropathy, corneal nerve regeneration, and tissue repair — all use cases built on its engineered ability to retain erythropoietin's tissue-protective effects without stimulating red blood cell production. The strongest evidence is in sarcoidosis-associated small fiber neuropathy, where a randomized, double-blind Phase 2 pilot trial showed significant improvement in neuropathic symptom scores and physical functioning over 4 weeks, followed by a study demonstrating a 23% increase in corneal nerve fiber density at the 4 mg dose confirmed by confocal microscopy — an objective regenerative endpoint that is unusual in the peripheral neuropathy literature. The caveats are real: sample sizes are small (22-48 patients), Phase 3 has not been conducted, and ARA-290 has orphan drug designation but no approval in any indication. Its mechanism — selective activation of the innate repair receptor expressed only on injured tissue — is well-characterized and differentiates it from broadly immunosuppressive therapies. The honest framing is a well-engineered molecule with small but methodologically solid Phase 2 evidence in a specific neuropathy niche, pending the Phase 3 development it has not yet received.

History & Discovery

ARA-290 (cibinetide) emerged from work mapping which surface of the erythropoietin (EPO) molecule is responsible for its tissue-protective effects versus its erythropoietic effects. Researchers identified helix B as the structural region engaging the innate repair receptor (IRR) — the heteromer of EPOR and the β-common receptor (CD131) that is transiently expressed on injured tissue. By synthesising an 11-amino-acid peptide modelled on the aqueous-facing surface of helix B (pyroglutamate-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser), the program produced a molecule that retains EPO's cytoprotective and anti-inflammatory signalling while losing affinity for the homodimeric EPOR2 on erythroid precursors. The peptide was advanced into human trials by Araim Pharmaceuticals, anchored by the 2012 randomised, double-blind pilot study in sarcoidosis-associated small fiber neuropathy that remains the reference trial. Subsequent Phase 2 work extended the program into type 2 diabetic neuropathy and corneal nerve regeneration, and ARA-290 has received orphan drug designation for sarcoidosis-associated neuropathy.

How It Works

ARA-290 is a fragment of erythropoietin (EPO) — the hormone that stimulates red blood cell production — but redesigned to keep EPO's healing effects without boosting blood cells. It activates a special receptor (the innate repair receptor) that only appears on damaged tissues, telling them to repair, reduce inflammation, and protect against further damage. The most studied application is nerve pain, where ARA-290 appears to help damaged small nerve fibers regenerate.

ARA-290 (pyroglutamate-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser) is derived from the aqueous-facing surface of helix B of erythropoietin. It does not activate the classical homodimeric EPOR2 receptor on erythroid precursors (explaining the absence of erythropoietic effects). Instead, it binds the innate repair receptor (IRR) — a heterocomplex of EPOR and the β-common receptor (βcR/CD131) that is transiently expressed on tissues undergoing injury or inflammation. IRR activation triggers JAK2/STAT3, PI3K/Akt, and MAPK pathways, leading to: inhibition of apoptotic signaling, suppression of pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β), promotion of cell survival, enhanced nerve fiber regeneration, and reduced oxidative stress. In small fiber neuropathy, ARA-290 appears to restore unmyelinated C-fiber function and support epidermal and corneal nerve fiber regrowth. Because IRR is not expressed on healthy tissue, the anti-inflammatory and protective effects are localized to injury sites — a tissue-specific pharmacology that differentiates ARA-290 from broadly immunosuppressive therapies.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about ARA-290:

• 01Phase 3 trials have not been conducted in any indication, including the sarcoidosis-associated small fiber neuropathy lead program that has the strongest Phase 2 signal.
• 02Whether the corneal nerve fiber density increase observed at the 4 mg dose translates to durable functional improvement (sensory thresholds, neuropathic pain scores) over longer follow-up is unresolved.
• 03Optimal route (subcutaneous vs. intravenous), dose, and treatment duration for chronic neuropathy management have not been settled — trial protocols have varied across the program.
• 04Efficacy outside sarcoidosis and type 2 diabetes — for example in chemotherapy-induced peripheral neuropathy, chronic inflammatory demyelinating polyneuropathy, or idiopathic small fiber neuropathy — has not been tested in adequately powered trials.
• 05Whether nerve regeneration persists after discontinuation, or whether ongoing dosing is required to maintain benefit, is unknown.
• 06Long-term safety beyond the 4-week to several-month trial durations published to date has not been characterised.

Forms & Administration

ARA-290 has been studied via subcutaneous and intravenous administration. In the sarcoidosis SFN trial, dosing was 2 mg IV three times weekly for 4 weeks. Corneal nerve fiber studies used 4 mg doses. Subcutaneous administration is the more practical route for extended use. ARA-290 is not available as an FDA-approved therapy; access is restricted to research settings. As with any investigational peptide, use should only occur under qualified medical supervision in a research or specialty context.

Common Questions

Who ARA-290 Is NOT For

Drug & Supplement Interactions

No clinically documented drug-drug interactions have been reported for ARA-290 in the published Phase 2 trials, but the interaction profile has not been systematically studied. Theoretically, because ARA-290 acts on the innate repair receptor to suppress pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and modulate JAK2/STAT3 signalling, additive effects with biologic immunomodulators (TNF inhibitors, IL-6 antagonists, JAK inhibitors) are plausible but unquantified. Unlike full-length EPO, ARA-290 does not raise hematocrit, so the cardiovascular-risk interactions associated with erythropoiesis-stimulating agents (with antihypertensives, anticoagulants, or in patients with iron-deficiency states) are not expected to apply. The honest framing is that interaction data are absent rather than reassuring — patients on complex regimens should review use with the prescribing investigator.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions